BACKGROUND: Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease. METHODS: Retrospective analysis of a cohort of advanced stage NB survivors followed in a late effect clinic at a single institution. Screening tests to detect late effects were tailored depending on the individual's treatment exposures. RESULTS: The study included 63 survivors (31 males). The median age at diagnosis was 3.0 years. The median follow-up from diagnosis was 7.06 years. All patients had surgery and received chemotherapy, 89% received radiation therapy (RT), 62% immunotherapy, and 56% autologous stem cell transplant. Late complications were detected in 95% of survivors and included: hearing loss (62%), primary hypothyroidism (24%), ovarian failure (41% of females), musculoskeletal (19%), and pulmonary (19%) abnormalities. The majority of complications were moderate, with only 4% being life-threatening. Survivors who received cisplatin were at greater risk to develop hearing loss compared to those not so treated (OR 9.74; 95% CI: 0.9-101.6). A total dose of cyclophosphamide greater than 7.4 g was associated with ovarian failure (P = 0.02). CONCLUSIONS: Late complications occur frequently in survivors of advanced stage NB. The majority of these problems are of mild-moderate severity. Long-term follow-up (LFTU) and screening of this population is essential. (c) 2004 Wiley-Liss, Inc.
BACKGROUND: Few studies have assessed late effects in neuroblastoma (NB) survivors, particularly those with advanced stage disease. METHODS: Retrospective analysis of a cohort of advanced stage NB survivors followed in a late effect clinic at a single institution. Screening tests to detect late effects were tailored depending on the individual's treatment exposures. RESULTS: The study included 63 survivors (31 males). The median age at diagnosis was 3.0 years. The median follow-up from diagnosis was 7.06 years. All patients had surgery and received chemotherapy, 89% received radiation therapy (RT), 62% immunotherapy, and 56% autologous stem cell transplant. Late complications were detected in 95% of survivors and included: hearing loss (62%), primary hypothyroidism (24%), ovarian failure (41% of females), musculoskeletal (19%), and pulmonary (19%) abnormalities. The majority of complications were moderate, with only 4% being life-threatening. Survivors who received cisplatin were at greater risk to develop hearing loss compared to those not so treated (OR 9.74; 95% CI: 0.9-101.6). A total dose of cyclophosphamide greater than 7.4 g was associated with ovarian failure (P = 0.02). CONCLUSIONS: Late complications occur frequently in survivors of advanced stage NB. The majority of these problems are of mild-moderate severity. Long-term follow-up (LFTU) and screening of this population is essential. (c) 2004 Wiley-Liss, Inc.
Authors: Brian H Kushner; Stephen S Roberts; Danielle N Friedman; Deborah Kuk; Irina Ostrovnaya; Shakeel Modak; Kim Kramer; Ellen M Basu; Nai-Kong V Cheung Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Brian H Kushner; Nai-Kong V Cheung; Christopher A Barker; Kim Kramer; Shakeel Modak; Karima Yataghene; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-08 Impact factor: 7.038
Authors: Tseng Tien Huang; Yan Chen; Andrew C Dietz; Yutaka Yasui; Sarah S Donaldson; Dennis C Stokes; Marilyn Stovall; Wendy M Leisenring; Charles A Sklar; Lisa R Diller; Ann C Mertens; Gregory T Armstrong; Daniel M Green; Leslie L Robison; Kirsten K Ness Journal: Pediatr Blood Cancer Date: 2013-10-11 Impact factor: 3.167
Authors: Daniel J Zheng; Kevin R Krull; Yan Chen; Lisa Diller; Yutaka Yasui; Wendy Leisenring; Pim Brouwers; Rebecca Howell; Jin-Shei Lai; Lyn Balsamo; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Nina S Kadan-Lottick Journal: Cancer Date: 2018-06-11 Impact factor: 6.860
Authors: Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Karen Wasilewski-Masker; Louis S Constine; Leslie L Robison; Kirsten K Ness Journal: Curr Pediatr Rev Date: 2014
Authors: Jorge Delgado; Diego Jaramillo; Nancy A Chauvin; Michelle Guo; Mackenzie S Stratton; Hannah E Sweeney; Christian A Barrera; Sogol Mostoufi-Moab Journal: Pediatr Radiol Date: 2019-05-04
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162
Authors: Shakeel Modak; Brian H Kushner; Michael P LaQuaglia; Kim Kramer; Nai-Kong V Cheung Journal: Eur J Cancer Date: 2008-11-06 Impact factor: 9.162
Authors: Sara M Federico; Samuel L Brady; Alberto Pappo; Jianrong Wu; Shenghua Mao; Valerie J McPherson; Alison Young; Wayne L Furman; Robert Kaufman; Sue Kaste Journal: Pediatr Blood Cancer Date: 2015-01-13 Impact factor: 3.167